Molecular heterogeneity in glioblastoma: Potential clinical implications

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Parker, Nicole Renee ^a   Khong, Peter ^a   Parkinson, Jonathon Fergus ^a,b   Howell, Viive Maarika ^a   Wheeler, Helen Ruth ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Biomarkers; Glioblastoma; Glioma; Heterogeneity; Intra tumoral heterogeneity; Molecular; transcriptional subtype

Indexed keywords

CHITINASE 3 LIKE 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LACTATE DEHYDROGENASE A; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN PMS2; NEUROFIBROMIN; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN MDMX; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; RINDOPEPIMUT; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; ATRX GENE; BIOPSY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL HETEROGENEITY; CPG ISLAND; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENOTYPE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; MOLECULAR TYPING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; SANGER SEQUENCING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84923608597     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00055     Document Type: Article

References (87)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 114(2):97-109. doi: 10.1007/s00401-007-0243-4. PubMed PMID: 17618441; PubMed Central PMCID: PMC1929165.
2. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 108(3):479-85. doi: 10.1038/bjc.2012.581. PubMed PMID: 23299535; PubMed Central PMCID: PMC3593543.
3. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer (2000).
4. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 64(19):6892-9. Epub 2004/10/07. doi: 64/19/6892 [pii]10.1158/0008-5472.CAN-04-1337. PubMed PMID: 15466178.
5. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17(1):98-110. doi: 10.1016/j.ccr.2009.12.020. PubMed PMID: 20129251; PubMed Central PMCID: PMC2818769.
6. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 9(3):157-73. doi: 10.1016/j.ccr.2006.02.019. PubMed PMID: 16530701.
7. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The Somatic Genomic Landscape of Glioblastoma. Cell (2013) 155(2):462-77. doi: DOI 10.1016/j.cell.2013.09.034. PubMed PMID: WOS:000325719800021.
8. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. PubMed PMID: 20399149; PubMed Central PMCID: PMC2872684.
9. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 321(5897):1807-12. doi: 10.1126/science.1164382. PubMed PMID: 18772396; PubMed Central PMCID: PMC2820389.
10. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol (2013) 126(3):443-51. Epub 2013/08/02. doi: 10.1007/s00401-013-1156-z. PubMed PMID: 23904111.
11. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 29(34):4482-90. Epub 2011/10/26. doi: JCO.2010.33.8715 [pii] 10.1200/JCO.2010.33.8715. PubMed PMID: 22025148; PubMed Central PMCID: PMC3236649.
12. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature (2014) 512(7514):324-7. Epub 2014/07/22. doi: nature13387 [pii] 10.1038/nature13387. PubMed PMID: 25043048.
13. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 27(35):5874-80. Epub 2009/11/11. doi: JCO.2009.23.6497 [pii] 10.1200/JCO.2009.23.6497. PubMed PMID: 19901110.
14. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol (2013) 31(3):337-43. Epub 2012/10/17. doi: JCO.2012.43.2674 [pii] 10.1200/JCO.2012.43.2674. PubMed PMID: 23071247; PubMed Central PMCID: PMC3732012.
15. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol (2013) 31(3):344-50. Epub 2012/10/17. doi: JCO.2012.43.2229 [pii] 10.1200/JCO.2012.43.2229. PubMed PMID: 23071237.
16. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3(7):709-22. Epub 2012/08/08. doi: 588 [pii]. PubMed PMID: 22869205; PubMed Central PMCID: PMC3443254.
17. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 462(7274):739-44. Epub 2009/11/26. doi: nature08617 [pii]10.1038/nature08617. PubMed PMID: 19935646.
18. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol (2013) 16(5):686-95. Epub 2013/12/25. doi: not243 [pii]10.1093/neuonc/not243. PubMed PMID: 24366912.
19. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol (2010) 12(1):49-57. doi: 10.1093/neuonc/nop007. PubMed PMID: 20150367; PubMed Central PMCID: PMC2940562.
20. Allingham-Hawkins D, Lea A, Levine S. DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform. PLoS Curr (2010) 2:RRN1186. Epub 2010/10/26. doi: 10.1371/currents.RRN1186k/-/-/1i0b298tuv2uk/2 [pii]. PubMed PMID: 20972474; PubMed Central PMCID: PMC2957243.
21. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352(10):987-96. doi: 10.1056/NEJMoa043330. PubMed PMID: 15758009.
22. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer (2009) 101(1):124-31. Epub 2009/06/19. doi: 6605127 [pii] 10.1038/sj.bjc.6605127. PubMed PMID: 19536096.
23. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol (2010) 12(2):116-21. Epub 2010/02/13. doi: nop020 [pii]10.1093/neuonc/nop020. PubMed PMID: 20150378.
24. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol (2014) 10(7):372-85. Epub 2014/06/11. doi: nrneurol.2014.100 [pii] 10.1038/nrneurol.2014.100. PubMed PMID: 24912512.
25. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 352(10):997-1003. doi: 10.1056/NEJMoa043331. PubMed PMID: 15758010.
26. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 60(9):2368-71. Epub 2000/05/16. PubMed PMID: 10811111.
27. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol (2006) 24(27):4412-7. Epub 2006/09/20. doi: 24/27/4412 [pii] 10.1200/JCO.2006.06.9104. PubMed PMID: 16983109.
28. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 27(34):5743-50. Epub 2009/10/07. doi: JCO.2009.23.0805 [pii]10.1200/JCO.2009.23.0805. PubMed PMID: 19805672.
29. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 13(7):707-15. Epub 2012/05/15. doi: S1470-2045(12)70164-X [pii]10.1016/S1470-2045(12)70164-X. PubMed PMID: 22578793.
30. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 13(9):916-26. Epub 2012/08/11. doi: S1470-2045(12)70265-6 [pii]10.1016/S1470-2045(12)70265-6. PubMed PMID: 22877848.
31. Shinsato Y, Furukawa T, Yunoue S, Yonezawa H, Minami K, Nishizawa Y, et al. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget (2013) 4(12):2261-70. PubMed PMID: 24259277.
32. Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, et al. Novel MSH6 Mutations in Treatment-Naive Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation. Clin Cancer Res (2014) 20(18):4894-903. Epub 2014/08/01. doi: 1078-0432.CCR-13-1856 [pii]10.1158/1078-0432.CCR-13-1856. PubMed PMID: 25078279.
33. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer (2011) 129(3):659-70. doi: 10.1002/ijc.26083. PubMed PMID: 21425258.
34. Stark AM, Doukas A, Hugo HH, Mehdorn HM. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res (2010) 32(8):816-20. doi: 10.1179/016164110X12645013515052. PubMed PMID: 20223108.
35. Everhard S, Tost J, El Abdalaoui H, Criniere E, Busato F, Marie Y, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol (2009) 11(4):348-56. doi: 10.1215/15228517-2009-001. PubMed PMID: 19224763; PubMed Central PMCID: PMC2743215.
36. Grombacher T, Mitra S, Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis (1996) 17(11):2329-36. PubMed PMID: 8968045.
37. Fritz G, Tano K, Mitra S, Kaina B. Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol (1991) 11(9):4660-8. PubMed PMID: 1875945; PubMed Central PMCID: PMC361355.
38. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer (2004) 4(4):296-307. doi: 10.1038/nrc1319. PubMed PMID: 15057289.
39. Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer (2011) 11:35. doi: 10.1186/1471-2407-11-35. PubMed PMID: 21269507; PubMed Central PMCID: PMC3039628.
40. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2010) 6(1):39-51. doi: 10.1038/nrneurol.2009.197. PubMed PMID: 19997073.
41. Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs (2012) 21(9):1247-66. doi: 10.1517/13543784.2012.703177. PubMed PMID: 22731981.
42. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 11(4):1462-6. doi: 10.1158/1078-0432.CCR-04-1737. PubMed PMID: 15746047.
43. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 25(16):2288-94. doi: 10.1200/JCO.2006.08.0705. PubMed PMID: 17538175.
44. Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol (2012) 25(6):774-9. Epub 2012/09/26. doi: 10.1097/WCO.0b013e328359b0bc. PubMed PMID: 23007009.
45. Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol (2011) 29(22):3050-5. Epub 2011/06/29. doi: JCO.2011.34.8086 [pii]10.1200/JCO.2011.34.8086. PubMed PMID: 21709196.
46. Del Vecchio CA, Wong AJ. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther (2010) 12(6):741-54. Epub 2010/12/15. PubMed PMID: 21154166.
47. Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid (2012) 7:93-103. Epub 2012/10/12. doi: 10.2147/CE.S29001ce-7-093 [pii]. PubMed PMID: 23055947; PubMed Central PMCID: PMC3459544.
48. Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer (2014) 134(10):2437-47. Epub 2014/03/13. doi: 10.1002/ijc.28576. PubMed PMID: 24614983.
49. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Jr., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America (2013) 110(15):6021-6. doi: 10.1073/pnas.1303607110. PubMed PMID: 23530248; PubMed Central PMCID: PMC3625331.
50. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proceedings of the National Academy of Sciences of the United States of America (2013) 110(10):4009-14. doi: 10.1073/pnas.1219747110. PubMed PMID: 23412337; PubMed Central PMCID: PMC3593922.
51. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2010) 1805(1):105-17. doi: 10.1016/j.bbcan.2009.11.002. PubMed PMID: 19931353; PubMed Central PMCID: PMC2814927.
52. De Sousa EMF, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity--a multifaceted view. EMBO Rep (2013) 14(8):686-95. doi: 10.1038/embor.2013.92. PubMed PMID: 23846313; PubMed Central PMCID: PMC3736134.
53. Nickel GC, Barnholtz-Sloan J, Gould MP, McMahon S, Cohen A, Adams MD, et al. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One (2012) 7(4):e35262. doi: 10.1371/journal.pone.0035262. PubMed PMID: 22536362; PubMed Central PMCID: PMC3335059.
54. Giese A, Westphal M. Treatment of malignant glioma: a problem beyond the margins of resection. J Cancer Res Clin Oncol (2001) 127(4):217-25. Epub 2001/04/24. PubMed PMID: 11315255.
55. Mitchell P, Ellison DW, Mendelow AD. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol (2005) 4(7):413-22. Epub 2005/06/21. doi: S1474-4422(05)70118-6 [pii]10.1016/S1474-4422(05)70118-6. PubMed PMID: 15963444.
56. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med (2005) 353(8):811-22. Epub 2005/08/27. doi: 353/8/811 [pii]10.1056/NEJMra043666. PubMed PMID: 16120861.
57. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol (2006) 7(5):392-401. Epub 2006/05/02. doi: S1470-2045(06)70665-9 [pii]10.1016/S1470-2045(06)70665-9. PubMed PMID: 16648043.
58. Nowell PC. The clonal evolution of tumor cell populations. Science (1976) 194(4260):23-8. PubMed PMID: 959840.
59. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer (2010) 103(8):1139-43. doi: 10.1038/sj.bjc.6605912. PubMed PMID: 20877357; PubMed Central PMCID: PMC2967073.
60. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366(10):883-92. doi: 10.1056/NEJMoa1113205. PubMed PMID: 22397650.
61. Sprouffske K, Merlo LM, Gerrish PJ, Maley CC, Sniegowski PD. Cancer in light of experimental evolution. Curr Biol (2012) 22(17):R762-71. doi: 10.1016/j.cub.2012.06.065. PubMed PMID: 22975007; PubMed Central PMCID: PMC3457634.
62. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science (2013) 339(6127):1546-58. Epub 2013/03/30. doi: 339/6127/1546 [pii]10.1126/science.1235122. PubMed PMID: 23539594.
63. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 72(19):4875-82. doi: 10.1158/0008-5472.CAN-12-2217. PubMed PMID: 23002210.
64. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature (2001) 414(6859):105-11. doi: 10.1038/35102167. PubMed PMID: 11689955.
65. Cheshier SH, Kalani MY, Lim M, Ailles L, Huhn SL, Weissman IL. A neurosurgeon's guide to stem cells, cancer stem cells, and brain tumor stem cells. Neurosurgery (2009) 65(2):237-49; discussion 49-50; quiz N6. doi: 10.1227/01.NEU.0000349921.14519.2A. PubMed PMID: 19625901.
66. Larjavaara S, Mantyla R, Salminen T, Haapasalo H, Raitanen J, Jaaskelainen J, et al. Incidence of gliomas by anatomic location. Neuro Oncol (2007) 9(3):319-25. Epub 2007/05/25. doi: 15228517-2007-016 [pii]10.1215/15228517-2007-016. PubMed PMID: 17522333.
67. Lyons JG, Lobo E, Martorana AM, Myerscough MR. Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis (2008) 25(6):665-77. doi: 10.1007/s10585-007-9134-2. PubMed PMID: 18071912.
68. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res (2011) 71(12):4055-60. doi: 10.1158/0008-5472.CAN-11-0153. PubMed PMID: 21628493; PubMed Central PMCID: PMC3117065.
69. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 12(5):323-34. doi: 10.1038/nrc3261. PubMed PMID: 22513401.
70. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11(1):69-82. Epub 2007/01/16. doi: S1535-6108(06)00369-2 [pii]10.1016/j.ccr.2006.11.020. PubMed PMID: 17222791.
71. Hu YY, Fu LA, Li SZ, Chen Y, Li JC, Han J, et al. HIF--regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells. Cancer Lett (2014) 349(1):67-76. Epub 2014/04/08. doi: S0304-3835(14)00204-3 [pii]10.1016/j.canlet.2014.03.035. PubMed PMID: 24705306.
72. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2014) 343(6167):189-93. doi: 10.1126/science.1239947. PubMed PMID: 24336570.
73. Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proceedings of the National Academy of Sciences of the United States of America (2015) 112(3):851-6. Epub 2015/01/07. doi: 10.1073/pnas.1320611111. PubMed PMID: 25561528; PubMed Central PMCID: PMCPmc4311802.
74. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, et al. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol (2008) 87(1):71-8. doi: 10.1007/s11060-007-9486-PubMed PMID: 18004504.
75. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer (2007) 121(11):2458-64. doi: 10.1002/ijc.23020. PubMed PMID: 17691113.
76. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 20(6):810-7. doi: 10.1016/j.ccr.2011.11.005. PubMed PMID: 22137795.
77. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proceedings of the National Academy of Sciences of the United States of America (2012) 109(8):3041-6. doi: 10.1073/pnas.1114033109. PubMed PMID: 22323597; PubMed Central PMCID: PMC3286976.
78. Little SE, Popov S, Jury A, Bax DA, Doey L, Al-Sarraj S, et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res (2012) 72(7):1614-20. doi: 10.1158/0008-5472.CAN-11-4069. PubMed PMID: 22311673.
79. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 344(6190):1396-401. Epub 2014/06/14. doi: science.1254257 [pii]10.1126/science.1254257. PubMed PMID: 24925914; PubMed Central PMCID: PMC4123637.
80. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature (2013) 501(7467):355-64. Epub 2013/09/21. doi: nature12627 [pii]10.1038/nature12627. PubMed PMID: 24048068.
81. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, 2nd, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2010) 96(2):219-30. Epub 2009/06/30. doi: 10.1007/s11060-009-9950-0. PubMed PMID: 19562254.
82. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol (2008) 26(28):4659-65. Epub 2008/10/01. doi: 26/28/4659 [pii]10.1200/JCO.2008.16.9235. PubMed PMID: 18824712.
83. Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 355:135-69. Epub 2011/10/22. doi: 10.1007/82_2011_178. PubMed PMID: 22015553.
84. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol (2014) 16(4):567-78. Epub 2014/01/29. doi: not247 [pii]10.1093/neuonc/not247. PubMed PMID: 24470557.
85. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 10(12):1470-6. Epub 2008/11/18. doi: ncb1800 [pii]10.1038/ncb1800. PubMed PMID: 19011622; PubMed Central PMCID: PMC3423894.
86. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 30(11):1033-6. Epub 2012/11/10. doi: nbt.2403 [pii]10.1038/nbt.2403. PubMed PMID: 23138292; PubMed Central PMCID: PMC3827024.
87. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 38(4):468-73. Epub 2006/03/28. doi: ng1768 [pii]10.1038/ng1768. PubMed PMID: 16565718.